Low-dose protamine to facilitate earlier sheath removal from the femoral artery after peripheral endovascular intervention

Journal of Interventional Cardiology

Volumn 24, Issue 3, 2011, Pages 278-284

  Hanna, Nicholas ^a   Fiorilli, Paul ^a   Gaglia Jr , Michael A ^a   Torguson, Rebecca ^a   Vita, Antonia ^a   Ben Dor, Itsik ^a   Xue, Zhenyi ^a   Waksman, Ron ^a   Bernardo, Nelson L ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROTAMINE;

ACCESS VESSEL THROMBOSIS; ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FALSE ANEURYSM; FEASIBILITY STUDY; FEMALE; FEMORAL ARTERY; GROIN HEMATOMA; HEMATOMA; HUMAN; HYPERCHOLESTEROLEMIA; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL ENDOVASCULAR INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; SHEATH REMOVAL; THROMBOSIS; VASCULAR ACCESS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; COMBINED MODALITY THERAPY; ENDOVASCULAR PROCEDURES; FEASIBILITY STUDIES; FEMALE; FEMORAL ARTERY; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POSTOPERATIVE COMPLICATIONS; PROTAMINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959883862     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00642.x     Document Type: Article

References (38)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans Atlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-1312.
2. Carey D, Martin JR, Moore CA, et al. Complications of femoral artery closure devices. Catheter Cardiovasc Interv 2001;52:3-7. (Pubitemid 32066467)
3. Heuser JJ, Henry M. Textbook of Peripheral Vascular Interventions. 2nd ed. New York: Informa Healthcare, 2008.
4. Gray BH, Miller R, Langan EM, 3rd, et al. The utility of the starclose arterial closure device in patients with peripheral arterial disease. Ann Vasc Surg 2009;23:341-344.
5. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995;91:2882-2890.
6. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG investigators. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation of PTCA to improve longterm outcome with abciximab GP IIb/IIIa receptor blockade. J Am Coll Cardiol 1998;32:1619-1623.
7. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT investigators. Circulation 1995;91:2151-2157.
8. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis. J Am Coll Cardiol 1998;31:1518-1524. (Pubitemid 28273293)
9. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology 1989;170:921-940. (Pubitemid 19060349)
10. Matsi PJ, Manninen HI. Complications of lower-limb percutaneous transluminal angioplasty: A prospective analysis of 410 procedures on 295 consecutive patients. Cardiovasc Interv Radiol 1998;21:361-366. (Pubitemid 28452430)
11. Kiernan TJ, Ajani AE, Yan BP. Management of access site and systemic complications of percutaneous coronary and peripheral interventions. J Invasive Cardiol 2008;20:463-469.
12. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-337.
13. Stafford-Smith M, Lefrak EA, Qazi AG, et al. Members of the Global Perioperative Research Organization. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005;103:229-240.
14. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
15. Stedman TL. Stedman's Medical Dictionary. 25th ed. Baltimore, MD: Williams and Wilkins, 2001.
16. Lonn L, Olmarker A, Geterud K, et al. Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms. J Endovasc Ther 2004;11:570-576. (Pubitemid 39435086)
17. Starnes BW, O'Donnell SD, Gillespie DL, et al. Percutaneous arterial closure in peripheral vascular disease: A prospective randomized evaluation of the perclose device. J Vasc Surg 2003;38:263-271. (Pubitemid 41123251)
18. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med 1991;325:556-562.
19. Bogart MA. Time to hemostasis: A comparison of manual versus mechanical compression of the femoral artery. Am J Crit Care 1995;4:149-156.
20. Colapinto RF, Harty PW. Femoral artery compression device for outpatient angiography. Radiology 1988;166:890-891. (Pubitemid 18058966)
21. Bangalore S, Arora N, Resnic FS. Vascular closure device failure: Frequency and implications: A propensity-matched analysis. Circ Cardiovasc Interv 2009;2:549-556.
22. Dangas G, Mehran R, Kokolis S, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638-641. (Pubitemid 32835728)
23. Dunning J, Versteegh M, Fabbri A, et al, EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:73-92.
24. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45.
25. Kimmel SE, Sekeres M, Berlin JA, et al. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002;94:1402-1408. (Pubitemid 34556613)
26. Panos A, Orrit X, Chevalley C, et al. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur J Cardiothorac Surg 2003;24:325-327. (Pubitemid 36952212)
27. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol 1990;85:713-719. (Pubitemid 20141135)
28. Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989;320:886-892. (Pubitemid 19101592)
29. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: A systematic literature review. Basic Clin Pharmacol Toxicol 2008;103:192-196. (Pubitemid 352019729)
30. Michaels IA, Barash PG. Hemodynamic changes during protamine administration. Anesth Analg 1983;62:831-835. (Pubitemid 13044070)
31. Carr JA, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino) 1999;40:659-666.
32. Gupta SK, Veith FJ, Ascer E, et al. Anaphylactoid reactions to protamine: An often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery. J Vasc Surg 1989;9:342-350. (Pubitemid 19070017)
33. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-785. (Pubitemid 28455470)
34. Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung 1999;28:418-428.
35. Briguori C, Di Mario C, De Gregorio J, et al. Administration of protamine after coronary stent deployment. Am Heart J 1999;138:64-68. (Pubitemid 29331123)
36. Pan M, Súarez de Lezo J, Medina A, et al. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. Am J Cardiol 1997;80:1336-1338. (Pubitemid 27513336)
37. Ducas J, Chan MC, Miller A, et al. Immediate protamine administration and sheath removal following percutaneous coronary intervention: A prospective study of 429 patients. Catheter Cardiovasc Interv 2002;56:196-199. (Pubitemid 34568817)
38. Rossi ML, Zavalloni D, Scatturin M, et al. Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation. Expert Opin Pharmacother 2007;8:2017-2024. (Pubitemid 47505581)